Skip to main content

Articles Tagged With:

  • Business Developments

    After a period of about nine months apparently on hold, the clinical trial of the AbioCor replacement heart made by Abiomed (Danvers, Massachusetts) picked up speed last month, with the company reporting a second implant in January, the two most recent at Jewish Hospital in Louisville, Kentucky.
  • Agreements

    Aesculap (Center Valley, Pennsylvania) said it has been awarded a 24-month agreement with Premier for a complete array of neurosurgery products for the treatment of strokes, tumors and other cerebrovascular conditions. The multi-source agreement, in effect since Jan. 1, is Premiers first contract for neurosurgical products.
  • Personnel Files

    John Thero, chief financial officer at Abiomed (Danvers, Massachusetts), has resigned to pursue a venture-backed opportunity, the company said. Abiomeds controller, Charles Haaser, will serve as acting CFO until a new CFO is named.
  • Full February 1, 2003 Issue in PDF

  • Opioids, Ketorolac, and the Biliary Tract

    The authors sought to determine if opioid administration before nuclear hepatobiliary imaging delays common bile duct visualization and prolongs imaging.
  • ECG Review: How Many Chambers?

    The 12-lead ECG shown in the Figure was obtained from a 49-year-old African American man with a history of hypertension, alcohol abuse, and progressively increasing dyspnea. What might his echocardiogram show? How many cardiac chambers are likely to be enlarged?
  • Full February 2003 Issue in PDF

  • Pharmacologic Reperfusion for AMI: Combining GPIIb/IIIa Inhibitors with Reduced Dose Fibrinolytics

    Current pharmacologic reperfusion for acute myocardial infarction primarily involves the administration of fibrinolytic therapy. Recently, investigators have focused on combining fibrinolytic agents with platelet inhibitors, such as the glycoprotein IIb/IIIa inhibitor agents, to reduce complications and improve clinical outcome.
  • Should We Screen All OD Patients for Acetaminophen?

    The authors of this study proposed and tested the following clinical decision rule: Patients presenting to the ED after a deliberate overdose do not need paracetamol level testing if they: a) deny paracetamol ingestion; b) present with a Glasgow Coma Scale score of 15; c) understand English; and d) have not consumed an excessive amount of alcohol.
  • Special Feature: The Electrocardiogram in Wolff-Parkinson-White Syndrome

    In 1930, Wolff, Parkinson, and White described the combination of bundle-branch block, abnormally short PR interval, and paroxysms of tachycardia occurring in young, healthy patients with normal hearts.